Fennec Pharmaceuticals
FENC
64 hedge funds and large institutions have $87.7M invested in Fennec Pharmaceuticals in 2024 Q2 according to their latest regulatory filings, with 17 funds opening new positions, 26 increasing their positions, 11 reducing their positions, and 17 closing their positions.
136% more repeat investments, than reductions
Existing positions increased: 26 | Existing positions reduced: 11
0% more first-time investments, than exits
New positions opened: 17 | Existing positions closed: 17
1.02% less ownership
Funds ownership: 53.58% → 52.56% (-1%)
2% less funds holding
Funds holding: 65 → 64 (-1)
46% less capital invested
Capital invested by funds: $161M → $87.7M (-$73.4M)
60% less funds holding in top 10
Funds holding in top 10: 5 → 2 (-3)
94% less call options, than puts
Call options by funds: $1K | Put options by funds: $18K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$2.16M |
| 2 |
SCM
Solas Capital Management
Darien,
Connecticut
|
+$1.91M |
| 3 |
DCM
DG Capital Management
New York
|
+$1.02M |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$680K |
| 5 |
WG
Winton Group
London,
United Kingdom
|
+$556K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACM
AIGH Capital Management
Baltimore,
Maryland
|
-$6.34M |
| 2 |
EIM
Essex Investment Management
Boston,
Massachusetts
|
-$1.6M |
| 3 |
Renaissance Technologies
New York
|
-$1.56M |
| 4 |
LCM
Legato Capital Management
San Francisco,
California
|
-$635K |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$542K |
FENC Hedge Fund Activity: Q2 2024 in Review
64 of the 6,924 institutional investors tracked by Wall St. Rank reported a position in Fennec Pharmaceuticals (FENC) for Q2 2024, worth a combined $87.7M — down 46% from $161M a quarter earlier.
Fund positioning in FENC was balanced in Q2 2024: 17 funds opened new positions, 17 closed out, 26 added to existing stakes and 11 trimmed.
The largest buyer was BlackRock, adding an estimated $2.16M. The largest seller was AIGH Capital Management, exiting entirely with an estimated $6.34M sold.
- 64 institutional investors held Fennec Pharmaceuticals (FENC) as of Q2 2024, down from 65 in Q1 2024.
- Funds reported $87.7M of Fennec Pharmaceuticals stock for Q2 2024, down 46% quarter-over-quarter.
- 17 funds opened new Fennec Pharmaceuticals positions in Q2 2024 and 17 closed out, a net change of 0 holders.
- The largest Fennec Pharmaceuticals buyer in Q2 2024 was BlackRock, an estimated $2.16M added.
- The largest Fennec Pharmaceuticals seller in Q2 2024 was AIGH Capital Management, an estimated $6.34M sold.
Based on aggregated 13F filings for Q2 2024.